Sign In
Buy HIMS
$27.51
+0 (+0%)
At Close: Jun 03, 2026
Hims & Hers Introduces Labs With Annual Plans For Comprehensive Testing
01:35pm, Friday, 14'th Nov 2025
Hims & Hers Health, Inc. (NYSE: HIMS) announced the launch of Labs, a new way for customers to understand their overall health and identify ways to improve and maintain it.
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the launch of Labs, a new way for customers to understand their overall
Hims & Hers Bets on Lab Testing to Boost Growth
11:49am, Thursday, 13'th Nov 2025
The telehealth platform expects the new offering to add to its user base as it draws customers looking to prevent future health issues.
2 Quality Healthcare Stocks That Could Build a Strong Foundation for Beginner Investors
04:40am, Thursday, 13'th Nov 2025
These stocks have a lot more to offer than GLP-1 success. Eli Lilly is one of the oldest pharmaceutical companies in the world, is insanely profitable, and boasts a wide range of portfolio stars.
Hims & Hers Scales Technology-Enabled, Vertically Integrated Care
01:45pm, Tuesday, 11'th Nov 2025
HIMS deepens its technology-enabled care model with new offerings in GLP-1 weight loss, hormone health, and custom treatments.
3 Overvalued Stocks to Sell
11:20am, Tuesday, 11'th Nov 2025
These are among the most overvalued stocks that Morningstar covers.
Hims & Hers: Fast-Fashion Healthcare Is The Future (Rating Upgrade)
11:56am, Monday, 10'th Nov 2025
We're turning bullish on Hims & Hers now that we believe the worst is priced in. Q3 results confirm that the growth story remains centered around personalized plans driving 50% Y/Y revenue growth. Hen
Hims & Hers Revenue Continues to Surge. Is It Time to Buy the Stock?
04:35am, Sunday, 09'th Nov 2025
Hims & Hers continues to generate strong revenue growth. The company said it was in active discussion with Novo Nordisk to bring back Wegovy to its platform.
Hims & Hers Expands AI-Driven Personalized and Subscription-Based Care
01:46pm, Friday, 07'th Nov 2025
HIMS expands its AI-powered, subscription-based care model globally, backed by $870 million in fresh funding for growth.
Is Most-Watched Stock Hims & Hers Health, Inc. (HIMS) Worth Betting on Now?
10:00am, Friday, 07'th Nov 2025
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hims & Hers Stock Slips Post Y/Y Q3 Earnings Decline, Margins Contract
01:15pm, Wednesday, 05'th Nov 2025
HIMS reports lower third-quarter 2025 earnings even as revenue and subscriber growth remain strong across its channels.
Why Hims & Hers Stock May Be a Buy After Mixed Q3 Results
10:42am, Wednesday, 05'th Nov 2025
Hims & Hers Health Inc. NYSE: HIMS stock is holding onto a slight gain the day after the company delivered a mixed third-quarter earnings report. The caution centers around the company's valuation, wh
Hims & Hers: GLP-1 Partnership Could Unlock Value
07:02am, Wednesday, 05'th Nov 2025
Hims & Hers Health reported strong 3Q25 revenue growth of 49% YoY, despite a GAAP EPS miss and shares falling post-earnings. HIMS is expanding its offerings, including testosterone and potential at-ho
Teacher Retirement System of Texas Purchases 6,925 Shares of Hims & Hers Health, Inc. $HIMS
05:00am, Wednesday, 05'th Nov 2025
Teacher Retirement System of Texas boosted its stake in shares of Hims and Hers Health, Inc. (NYSE: HIMS) by 26.5% during the second quarter, according to the company in its most recent Form 13F filin
OMCL vs. HIMS: Which Stock Is the Better Value Option?
12:41pm, Tuesday, 04'th Nov 2025
Investors with an interest in Medical Info Systems stocks have likely encountered both Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two companies is the best option for thos
